- Home
- NPCT vs CRVS Comparison
NPCT vs CRVS Comparison
Compare NPCT & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NPCT
- CRVS
- Stock Information
- Founded
- NPCT 2020
- CRVS 2014
- Country
- NPCT United States
- CRVS United States
- Employees
- NPCT N/A
- CRVS N/A
- Industry
- NPCT Investment Managers
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- NPCT Finance
- CRVS Health Care
- Exchange
- NPCT Nasdaq
- CRVS Nasdaq
- Market Cap
- NPCT 313.7M
- CRVS 305.4M
- IPO Year
- NPCT N/A
- CRVS 2016
- Fundamental
- Price
- NPCT $10.91
- CRVS $5.75
- Analyst Decision
- NPCT
- CRVS Strong Buy
- Analyst Count
- NPCT 0
- CRVS 4
- Target Price
- NPCT N/A
- CRVS $15.00
- AVG Volume (30 Days)
- NPCT 107.1K
- CRVS 518.7K
- Earning Date
- NPCT 01-01-0001
- CRVS 08-07-2025
- Dividend Yield
- NPCT 9.82%
- CRVS N/A
- EPS Growth
- NPCT N/A
- CRVS N/A
- EPS
- NPCT N/A
- CRVS N/A
- Revenue
- NPCT N/A
- CRVS N/A
- Revenue This Year
- NPCT N/A
- CRVS N/A
- Revenue Next Year
- NPCT N/A
- CRVS N/A
- P/E Ratio
- NPCT N/A
- CRVS N/A
- Revenue Growth
- NPCT N/A
- CRVS N/A
- 52 Week Low
- NPCT $8.58
- CRVS $2.54
- 52 Week High
- NPCT $10.63
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- NPCT 48.99
- CRVS 65.10
- Support Level
- NPCT $10.82
- CRVS $5.28
- Resistance Level
- NPCT $10.98
- CRVS $5.64
- Average True Range (ATR)
- NPCT 0.12
- CRVS 0.30
- MACD
- NPCT -0.01
- CRVS 0.03
- Stochastic Oscillator
- NPCT 48.15
- CRVS 77.70
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to seek total return through high current income and capital appreciation, while giving special consideration to certain impact and environmental, social and governance criteria.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).